Cargando…
High rate of virologic suppression with darunavir/ritonavir plus optimized background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil
OBJECTIVES: To assess the virologic and immunological response of darunavir/ritonavir plus optimized background therapy in highly antiretroviral-experienced HIV-infected patients in Brazil. METHODS: Prospective cohort study carried out in a tertiary center in Sao Paulo, Brazil. Three-class antiretro...
Autores principales: | Vidal, José Ernesto, Song, Alice Tung Wan, Matos, Maria Laura, Bartmann, Daniel, Anjos, Guilherme dos, Miranda, Érique José Peixoto de, Freitas, Ângela Carvalho, Dalben, Mirian de Freitas, Santana, Claudinei, Segurado, Aluísio Cotrim, Barreto, Cláudia Cortese, Hernández, Adrián Vladimir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427411/ https://www.ncbi.nlm.nih.gov/pubmed/23294644 http://dx.doi.org/10.1016/j.bjid.2012.08.022 |
Ejemplares similares
-
Erratum in «High rate of virologic supression with darunavir/ritonavir plus optimazed background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil»
por: Ernesto Vidal, José, et al.
Publicado: (2013) -
Long-term virologic and immunologic responses on darunavir/ritonavir – containing regimens among highly antiretroviral therapy-experienced patients: 7-year follow-up of a prospective cohort study in São Paulo, Brazil
por: Vidal, José E., et al.
Publicado: (2017) -
HIV-infected youths transitioning from pediatric to adult outpatient care in a teaching tertiary care hospital in São Paulo city, Brazil
por: Freitas, Angela Carvalho, et al.
Publicado: (2019) -
Who and Where are the University of São Paulo Medical School Graduates?
por: Gameiro, Gustavo Rosa, et al.
Publicado: (2019) -
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients
por: Gianotti, Nicola, et al.
Publicado: (2017)